Company Filing History:
Years Active: 2016-2019
Title: The Innovative Contributions of Eloic Colombo
Introduction
Eloic Colombo is a notable inventor based in Sherbrooke, Canada. He has made significant contributions to the field of medical science, particularly in the development of treatments for viral infections. With a total of three patents to his name, Colombo's work is recognized for its potential impact on public health.
Latest Patents
Colombo's latest patents focus on matriptase inhibitors and their applications against orthomyxoviridae infections, including influenza. The inventions provide novel compounds and compositions aimed at treating and preventing these viral infections. Additionally, these compounds are designed to inhibit tumor growth, progression, and metastasis, showcasing their dual utility in both infectious disease and cancer treatment.
Career Highlights
Colombo is associated with Socpra Sciences Sante Et Humaines S.e.c., where he continues to innovate in the field of health sciences. His work is characterized by a commitment to developing effective therapeutic solutions that address pressing health challenges.
Collaborations
Colombo collaborates with esteemed colleagues such as Martin Richter and Richard Leduc. Their combined expertise enhances the research and development efforts within their organization.
Conclusion
Eloic Colombo's contributions to medical science through his patents on matriptase inhibitors highlight his role as a key innovator in the fight against viral infections and cancer. His work exemplifies the importance of innovation in improving health outcomes.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.